drugset / Trial / NCT07625644
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
RandomizedParallel-groupSingle-blindTreatment
Summary
The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).
Timeline
- Start
- 2026-06
- Primary completion
- 2030-01
- Completion
- 2031-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BL-M14D1 | Unknown | — | Intravenous |
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Background | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Comparator | Lurbinectedin | Other / unclassified | 3.2 mg/m2 | Intravenous |